Myelofibrosis -- KOL insight

What combination trials do KOLs say will consolidate the first-line position of Novartis' Jakafi? Recent trial readouts for GSK's late-stage momelotinib have been received by KOLs with optimism but where do they see it delivering first-line value? KOLs assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and the following KOL Bulletins via the Attachments area.

Table of Contents

Executive summary (12)

Treatment algorithm

Research objectives (9)

JAK inhibitors (46)

• Marketed therapies (35)
  • Jakafi/Jakavi (ruxolitinib; Incyte/Novartis) (10)
  • Vonjo/Epjevy/Enpaxiq (pacritinib; CTI BioPharma) (15)
  • Inrebic (fedratinib; Bristol Myers Squibb) (10)
• Pipeline therapies (11)
  • Momelotinib (GlaxoSmithKline) (11)

Exportin-1 protein inhibitors (9)

• Xpovio (selinexor; Karyopharm Therapeutics) (9)
  • Key insights summary (9)

Phosphatidylinositol 3-kinase delta inhibitors (13)

• Parsaclisib (Incyte) (13)
  • Key insights summary (13)

Proto-oncogene protein c-Bcl-2 inhibitors (15)

• Navitoclax (AbbVie) (15)
  • Key insights summary (15)

TGF-beta superfamily protein inhibitors (10)

• Reblozyl (luspatercept; Acceleron Pharma/Bristol Myers Squibb) (10)
  • Key insights summary (10)

MDM2 inhibitors (9)

• Navtemadlin (Kartos Therapeutics) (9)
  • Key insights summary (9)

Bromodomain and extraterminal domain protein inhibitors (11)

• Pelabresib (MorphoSys) (11)
  • Key insights summary (11)

Telomerase inhibitors (12)

• Imetelstat (Geron Corporation) (12)
  • Key insights summary (12)

Lysine-specific demethylase 1 (LSD1) inhibitors (10)

• Bomedemstat (Imago Biosciences) (10)
  • Key insights summary (10)

Future treatment paradigm (10)

• Key insights summary (10)
  • Drugs that prolong the life of patients and prevent disease progression are unmet needs in myelofibrosis; KOLs also welcome the treatment of cytopenic patients and drugs that modify the disease (8)

Appendix (3)

• KOL details (3)
  • KOLs from North America (1)
  • KOLs from Europe (1)